ER-464195-01

ER-464195-01 is an orally active calreticulin (CRT) and integrin α subunits (ITGAs) binding inhibitor. ER-464195-01 inhibits leukocyte infiltration and subsequent inflammatory cascade reactions by dissociating the binding between CRT and ITGA. ER-464195-01 down-regulates the expression of pro-inflammatory genes (such as TNF-α, IL-1β, IL-6, IL-17f) induced by DSS (HY-116282C), and inhibit the phosphorylation of STAT3 and the production of serum amyloid A (SAA) . ER-464195-01 can be used for the study of inflammatory bowel disease (IBD) [1].

Product Specifications

CAS Number

[859218-37-4]

UNSPSC

12352005

Target

Interleukin Related; STAT; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Purity

99.72

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1(C)CC(C)(C)CC(C2=CC=CC=C2N3CCN(CCC)CC3)C1.Cl

Molecular Formula

C23H39ClN2

Molecular Weight

379.02

References & Citations

[1]Ohkuro M, et al. Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease. Nat Commun. 2018 May 17;9 (1) :1982.